CMS announces TrumpRx.gov expansion and $50 monthly Medicare price for some GLP weight‑loss drugs

CMS Administrator Dr. Oz told reporters that the administration is expanding a drug‑price transparency tool and pressing drugmakers to align U.S. prices with those abroad.

Dr. Oz said the administration added 160 drugs to TrumpRx.gov, taking the searchable list to over 750 entries, and reported roughly 12 million unique visitors and an estimated $500 million in savings since a recent publicity event. "This site gives everybody the ability to make important decisions about medications they're purchasing with full knowledge of what the cost of those medications are," he said.

The administrator described the broader pricing strategy as a set of "most‑favored nation" agreements negotiated with 17 major branded manufacturers that together account for more than 80% of the branded market. He said those agreements mean drugs will be priced in the United States at levels closer to what the companies charge overseas and that the White House’s economic advisers estimate about $600 billion in savings over the next decade from the program. "We're not telling pharmaceutical companies what to charge. We're saying to them, whatever you charge us, you got to charge the other folks," Dr. Oz said.

Separately, Dr. Oz announced a change affecting Medicare beneficiaries: beginning July 1, patients eligible for certain GLP (glucagon‑like peptide) weight‑loss products will be able to obtain them for $50 per month. "The list price, as you know, for these drugs is well over $1,000 a month," he said, adding that the reduced cost could produce downstream savings if the medicines are used appropriately to reduce complications such as diabetes and heart disease.

Dr. Oz said the product supply will come from brand manufacturers participating in the program and named two major producers in the space; the administration said the pricing arrangement is intended to preserve manufacturer participation while delivering lower out‑of‑pocket costs to beneficiaries.

Why it matters: The changes combine a transparency tool intended to let consumers comparison‑shop with a pricing approach that the administration says will lock in lower prices through voluntary agreements and potential statutory codification. Dr. Oz urged Congress to back legislation that would codify the administration's most‑favored‑nation arrangements so the savings persist after the current White House leaves office.

What’s next: The administration said the expanded database is live and that the $50 monthly benefit for eligible Medicare beneficiaries will begin July 1. Lawmakers and industry groups may press for more details about eligibility, the covered product list, and how the reduced beneficiary price will be implemented at pharmacy checkout.